Source: Interfolio F180


Mansun Law, PhD

Professor
Department of Immunology and Microbiology


 Email

Education

Ph.D. (Virology), University of Oxford, 2001
M.Phil. (Molecular Biology), The University of Hong Kong, 1998
B.S. (Biotechnology), The University of Hong Kong, 1995

Selected Publications

Salas, Jordan H.; Urbanowicz, Richard A.; Guest, Johnathan D.; Frumento, Nicole; Figueroa, Alexis; Clark, Kaitlyn E.; Keck, Zhenyong; Cowton, Vanessa M.; Cole, Sarah J.; Patel, Arvind H.; Fuerst, Thomas R.; Drummer, Heidi E.; Major, Marian; Tarr, Alexander W.; Ball, Jonathan K.; Law, Mansun; Pierce, Brian G.; Foung, Steven K.; Bailey, Justin R. An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development. Gastroenterology 2021, 562-574.

Yechezkel, Itai; Tzarum, Netanel; Law, Mansun From Structural Studies to HCV Vaccine Design. Viruses 2021.

Chen, Fang; Tzarum, Netanel; Lin, Xiaohe; Giang, Erick; Velazquez-moctezuma, Rodrigo; Augestad, Elias H.; Nagy, Kenna; He, Linling; Hernandez, Mayda; Fouch, Mallorie E.; Grinyo, Ariadna; Chavez, Deborah; Doranz, Benjamin J.; Prentoe, Jannick; Stanfield, Robyn L.; Lanford, Robert E.; Bukh, Jens; Wilson, Ian A.; Zhu, Jiang; Law, Mansun Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 2021, 781-796.e4.

Olson, Margaret E.; Law, Mansun; Janda, Kim D.; Giang, Erick; Belz, Tyson F. Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model. ACS Medicinal Chemistry Letters 2020, 2428-2432.

Chen, Fang; Lairson, Luke L.; Law, Mansun Into the Unknown: A Chemical Biology Approach Provides Mechanistic Insight into HCV Entry. Cell Chemical Biology 2020, 27, 767-769.
[View]

Tzarum, N.; Giang, E.; Kadam, R. U.; Chen, Fang; Nagy, K.; Augestad, E. H.; Velazquez-Moctezuma, R.; Keck, Z. Y.; Hua, Y. Z.; Stanfield, Robyn L.; Dreux, M.; Prentoe, J.; Foung, S. K.; Bukh, J.; Wilson, Ian A.; Law, Mansun An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Science Advances 2020, 6.
[View]